Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Comment by AdamEHon Feb 07, 2018 2:54am
153 Views
Post# 27516867

RE:RE:RE:RE:RE:RE:RE:Average wait for 510k FDA Approval

RE:RE:RE:RE:RE:RE:RE:Average wait for 510k FDA ApprovalWhy would a group of professional sales experts and GA… smart enough to take the company this far Come up with a strategy?   To release the number of orders they have received right around the FDA approval? IS that even a question…… Because FDA approval doesn’t attract any attention at all…
I feel these 2 NR’s would be a great back to back releases. Would market this company to investors and attract new players. Marketing …. Make yourself as loud as possible!
I was not stating he was with holding sales Financials. The thought of making an NR every time there is a “purchase order”, or a committed client sale is ridiculous. They could have 400 individual P.Os from many different clients. There has to be some substance to make a strong statement.
I feel once this approval is finalized they will start producing these devices and filling purchase orders. Just makes sense to me…. I could be wrong, but I doubt it…
I know VMS-PLUS isn’t out there yet… We are all waiting to know what the demand is. That’s the only factor that is holding this stock back. Its been many years to get here.
VMS was just an introductory to the market. Market tested it… told them what they wanted. Now customized to meet the expectations. Now on the home stretch… If I am wrong. I am wrong. I loose. And move on….. but I believe in this story…. If they have lots of P.O’s with FDA approval. Shes gone into dollar land. All these people with sell order under 2 dollars are going to be getting off the bus way to early and will be stuck chasing it for miles down the road.

FYI. The position for Clinical Applications Specialist was just taken off the Ventripoint website job posting   3 days ago. My assumption is ..this position was filled because it needed to be. To get these devices installed and operating for there clients.  Just my opinion,

Adam


Bullboard Posts